# Bicycle Therapeutics (stock symbol: BCYC) Logo in transparent PNG and SVG formats

## Bicycle Therapeutics Logo large

### Bicycle Therapeutics Logo large Download PNG (21.88 KB)

![Bicycle Therapeutics Logo large Download PNG (21.88 KB)](/img/orig/BCYC_BIG-801ee736.png)

### Bicycle Therapeutics Logo large Download SVG (1.86 KB)

![Bicycle Therapeutics Logo large Download SVG (1.86 KB)](/img/orig/BCYC_BIG-846ab2e3.svg)

## Bicycle Therapeutics Logo icon format

### Bicycle Therapeutics Logo icon format Download PNG (25.25 KB)

![Bicycle Therapeutics Logo icon format Download PNG (25.25 KB)](/img/orig/BCYC-0214b90f.png)

### Bicycle Therapeutics Logo icon format Download SVG (645 Bytes)

![Bicycle Therapeutics Logo icon format Download SVG (645 Bytes)](/img/orig/BCYC-c22fe2cb.svg)

## Bicycle Therapeutics Logo large for dark backgrounds

### Bicycle Therapeutics Logo large for dark backgrounds Download PNG (21.88 KB)

![Bicycle Therapeutics Logo large for dark backgrounds Download PNG (21.88 KB)](/img/orig/BCYC_BIG.D-0df4994b.png)

### Bicycle Therapeutics Logo large for dark backgrounds Download SVG (1.86 KB)

![Bicycle Therapeutics Logo large for dark backgrounds Download SVG (1.86 KB)](/img/orig/BCYC_BIG.D-ce7cba53.svg)

## Bicycle Therapeutics Logo icon format for dark backgrounds

### Bicycle Therapeutics Logo icon format for dark backgrounds Download PNG (25.25 KB)

![Bicycle Therapeutics Logo icon format for dark backgrounds Download PNG (25.25 KB)](/img/orig/BCYC.D-387bc6b4.png)

### Bicycle Therapeutics Logo icon format for dark backgrounds Download SVG (645 Bytes)

![Bicycle Therapeutics Logo icon format for dark backgrounds Download SVG (645 Bytes)](/img/orig/BCYC.D-e472d004.svg)

## About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

1. Website domain: bicycletherapeutics.com
2. Employees: 119
3. Marketcap: $0.59 Billion USD


## Categories
- [x] ðŸ‡¬ðŸ‡§ United Kingdom
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
